Clinical Trial

Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS

Name: Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS — clinical trial record (NCT07498634)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 3

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, and parallel grouping study. Study procedures: The screening period does not exceed 4 weeks, including 16 weeks for initial treatment, 28 weeks for maintenance treatment and 8 weeks for safety follow-up.

Trial Details

NCT Number	NCT07498634
Lead Sponsor	Zhejiang Kanova Biopharmaceutical Co., LTD
Conditions	Phase III
Enrollment	323 participants
Start Date	2023-09-21
Primary Completion	2025-08-01 (estimated)
Study Completion	2025-11-14 (estimated)
Updated on ClinicalTrials.gov	2026-03-27